This document presents a strategic framework, aimed towards the development of sustainable global, regional and national plans relating to laboratory biorisk management.
Each year, the WHO Global TB Report provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets.
The... 2021 edition of the report has been produced in a new and more web-centric format. This is designed to make the content available in smaller (more “bite-sized”) chunks that are easier to read, digest, navigate and use. There is a short and slim report PDF with 30 pages of main content plus six short annexes. This is accompanied by expanded and more detailed digital content on web pages. The total amount of content remains similar to that of previous years.
Available in English, French, Arabic and Chinese
more
In the spirit of the Sustainable Development Goals, WHO and the International Labour Organization (ILO) produce the WHO/ILO Joint Estimates of the Work-related Burden of Disease and Injury (WHO/ILO Joint Estimates). The WHO/ILO Joint Estimates quantify the population exposed to occupational risk fac...tors and amount health loss caused by these exposures. Global, regional and national estimates are produced of the numbers of deaths and disability-adjusted life years that can be attributed to exposure to selected occupational risk factors. Estimates are produced disaggregated by sex and age group.
more
Technical Update
Areas of Africa endemic for Buruli ulcer (BU), caused by Mycobacterium ulcerans, also have a high prevalence of human immunodeficiency virus (HIV), with adult prevalence rates between 1% and 5% (Maps). However, there is limited information on the prevalence of BU–HIV coinfection.... Preliminary
evidence suggests that HIV infection may increase the risk of BU disease (1–3). In the Médecins Sans Frontières project in Akonolinga, Cameroon, HIV prevalence was approximately 3–6 times higher among BU patients than the regional estimated HIV prevalence (2). Similarly in Benin and Ghana, BU
patients were 8 times and 3 times respectively more likely to have HIV infection than those without BU (1, 3). Further study is needed to clarify this association and enhance knowledge about the prevalence ofBU–HIV coinfection in endemic areas.
more
This document provides interim guidance for effective risk communication around Zika virus transmission and potential complications. A causal relationship between Zika virus infection and these potential complications has not yet been proven. In this uncertainty, effective communication strategies s...hould be implemented to enable people to take the best informed decisions about protecting themselves, their families and communities. This interim guidance is intended to be used by risk and health communication managers, staff and volunteers at global, regional or country level; communications professionals; anthropologists; sociologists; healthcare providers;hospital administrators; community leaders; programme managers;
and policymakers.
more
AWaRe – a new WHO tool to help countries improve antibiotic treatment, increase access and reduce resistance. We can reduce or even reverse antibiotic resistance by using antibiotics more responsibly. But how do we do that and still ensure that patients are treated effectively?WHO has developed a ...tool to help global, regional and national decision-making on which antibiotics to use when. The tool indexes the most effective antibiotics into three groups – ACCESS, WATCH, RESERVE (AWaRe for short). Evidence shows that to optimize use of antibiotics and reduce resistance, countries should increase the proportion of ACCESS antibiotics to correspond to at least 60% of total national consumption.
more
WHO would like to express its gratitude and appreciation to all Member States that provided information to the WHO survey on policies and activities at the national level in the area of antimicrobial resistance. The contribution of staff in WHO Regional and Country Offices has been invaluable: in ga...ther-ing original data and information from Member States, in supporting the process of aggregation of these data; and in reviewing the regional analysis of the findings that reflect the country situation at the point when the survey was conducted. The support and commitment of the members of the WHO Task Force on Antimicrobial Resistance, comprising WHO staff from Headquarters and Regional Offices has, is also acknowledged.
more
Tuberculosis (TB) prevention is essential for reaching the End TB targets in the South-East Asia Region (SEAR) of World Health Organization (WHO)1. The targets of 80% reduction in TB incidence rate and 90% reduction in TB mortality by 2030 (compared to 2015 levels) can be achieved only with addition...al interventions aimed at preventing TB, according to epidemiological modelling studies commissioned by the WHO South-East Asia Regional Office (WHO SEARO). Optimal implementation of TB preventive treatment (TPT) is a critical intervention to accelerate reduction in TB burden in the SEA Region, which bears nearly 43% of the global TB burden. TPT by itself has the potential to reduce the overall annual TB incidence rates by 8.3% (95% CrI 6.5–10.8) relative to 2015.
more
Report of an intensive legal training and capacity-building workshop on law and noncommunicable diseases (Moscow, 30 May–3 June 2016)
The report summarizes important issues, themes and topics discussed during the meeting in Moscow, ranging from the design and implementation of legislation, reconc...iling public health objectives with international trade and investment law commitments, to examples of regional integration, such as the European Union and the Eurasian Economic Union.
more
The purpose of this field guide is to provide comprehensive information on planning and implementing high-quality3 SIAs for injectable vaccines and highlight the opportunities to strengthen RI and surveillance. The guide uses measles–rubella SIAs as the main example throughout, but the informatio...n provided aims to be applicable to SIAs delivering any injectable vaccine. It can serve as a reference for the preparation of regional/national SIA field guides and materials.
more
5 May 2021
This Information Note is intended to assist national TB programmes and health personnel worldwide to maintain essential tuberculosis (TB) services during the COVID-19 pandemic and in the recovery phase. It is important that recent progress made in TB prevention and care is not reversed b...y COVID-19. The WHO Global TB Programme, along with WHO regional and country offices, developed this note in response to questions received from Member States and other partners since the start of the pandemic. The note includes references to other published WHO information products relevant to TB practitioners. WHO continues to monitor the situation closely for any changes that may influence this note and will issue updates should any factors change.
more
The meningitis road map has been designated as a flagship global strategy of the WHO’s Thirteenth General Programme of Work, 2019–2023 and is an essential component in achieving universal health coverage.
The road map will reinforce and combine with wider initiatives, such as those aimed at s...trengthening primary health care and health systems, increasing immunization coverage, improving global health security, fighting antimicrobial resistance and advocating for the rights of persons with disabilities. It will complement other global control strategies, such as those addressing sepsis, pneumonia, tuberculosis and HIV. Implementation will be a challenge for all countries across the world, but especially in resource-poor settings where the burden of meningitis is greatest. The targets for the visionary and strategic goals will be adapted to regional and local contexts.
more
More than two years since the first SARS-CoV-2 infections were reported, the COVID-19 pandemic remains an acute global emergency. In this Strategic Preparedness, Readiness and Response plan for 2022, WHO sets out a number of key strategic adjustments that, if implemented rapidly and consistently at ...national, regional, and global levels, will enable the world to end the acute phase of the pandemic.
more
Together for One Health. Building on the momentum of increased collaboration, the WHO, FAO, OIE and UNEP have developed a Strategic Framework for collaboration on antimicrobial resistance (AMR). This Framework reflects the joint work of the four organizations to advance a One Health response to AMR ...at the global, regional and country level. It broadly supports the implementation of the five pillars of the Global Action Plan on AMR, as well as strengthening global AMR governance.
more
This document outlines the working structure and guiding principles for collaboration of COVAX, the Vaccines pillar of the Access to COVID-19 Tools Accelerator (ACT-A). The working structure of COVAX continues to adapt to emerging needs and the changing trajectory of the pandemic. Some components of... the pandemic response capabilities united under COVAX may eventually be integrated into regional, national and sub national health systems, routine immunization programmes and future global pandemic preparedness and response (PPR) structures. Therefore, the working structures outlined in this document continue to evolve and the document provides a snapshot of the COVAX ways of working in the first half of 2022.
more
Snake-bites are well-known medical emergencies in many parts of the world, especially in rural areas. Agricultural workers and children are the most affected. The incidence of snake-bite mortality is particularly high in South-East Asia. Rational use of snake anti-venom can substantially reduce mort...ality and morbidity due to snake bites. These Guidelines are a revised and updated version of similar guidelines published by the WHO Regional Office in South-East Asia in 1999. These guidelines aim to promote the rational management of snake-bite cases in various health facilities where trained health functionaries and quality snake antivenom are available.
more
Un suivi et une évaluation efficaces sont nécessaires pour atteindre l’objectif d’élimination de la filariose lymphatique (FL). Après le traitement médicamenteux de masse (TMM) conformément aux lignes directrices élaborées par l’OMS, des programmes doivent être mis en œuvre afin de d...éterminer si les interventions ont permis de réduire la prévalence de l’infestation à un niveau en deçà duquel sa transmission ne pourra vraisemblablement pas perdurer. L’enquête d’évaluation
de la transmission (TAS) a été conçue de manière à offrir une structure simple et robuste afin de déterminer si la prévalence de la filariose lymphatique chez des enfants de 6–7 ans est inférieure à un seuil préalablement déterminé. Le TAS fournit aux administrateurs de programmes les informations factuelles nécessaires pour décider de l’opportunité d’arrêter le TMM. Le TAS garantit aux pouvoirs publics que les programmes nationaux ont atteint leur objectif d’élimination de la FL.
Ce guide a été conçu pour enseigner aux membres du personnel des programmes nationaux d’élimination de la FL, notamment le personnel de santé aux niveaux régional et de district, les éléments essentiels des programmes nationaux de suivi et d’évaluation pour l’élimination de la FL. Le guide est axé sur la planification et la mise en œuvre du TAS afin de pouvoir décider de l’opportunité
d’interrompre le TMM et de commencer la surveillance post-TMM.
more
The Pandemic Influenza Pandemic (PIP) Framework's Partnership Contribution (PC) High-Level Implementation Plan III (HLIP III) outlines the strategy for strengthening global pandemic influenza preparedness from 2024 to 2030. HLIP III takes into consideration the lessons learned from the response to t...he COVID-19 pandemic, the gains made over time, including from previous HLIPs, and the broader programmatic and policy context in order to address gaps in pandemic influenza preparedness. Implementation of HLIP III will strengthen global, regional, and country-level pandemic influenza preparedness.
more
Vaccines are powerful weapons in the fight against pandemic viruses as shown by responses to both the 2009 H1N1 influenza and the COVID-19 pandemics. However, planning for accessing, allocating and deploying vaccines in a pandemic situation is a complex endeavour, beset with multiple challenges at a...ll levels – local, regional and global. The World Health Organization (WHO) and its partners have prepared this revised guidance document to assist countries update their national deployment and vaccination plans (NDVPs) by leveraging global learnings from past pandemic responses, including the recent COVID-19 vaccination effort. The development and testing of a NDVP would not only advance pandemic preparedness efforts but would also have benefits in terms of increasing national capabilities to manage other health emergencies which require emergency vaccination campaigns.
more
This briefing note, which focuses on the measurement of violence against women with disability, is one in a series of methodological cbriefing notes for strengthening the measurement and data collection of violence against particular groups of women or specific aspects of violence against women. The...se briefing notes are meant for researchers, national statistics offices and others involved in data collection on violence against women. They have been developed as
part of the UN Women–World Health Organization Joint Programme on strengthening methodologies and measurement of and building national capacities for violence against women data (Joint Programme on Violence against Women Data). These briefing notes seek to contribute to strengthening the quality and availability of data on violence against women and hence enhance global, regional and national level monitoring of progress towards its elimination, including for the United Nations Sustainable Development Goal (SDG) target 5.2 on the elimination of all forms of violence against women and girls
more